Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* male or female subjects of any race, ages 18-60 inclusive, with a clinical diagnosis of schizophrenia~* experiencing an acute exacerbation of psychosis~Exclusion Criteria:~* any subject unable to provide informed consent~* any female subject who is pregnant or breast-feeding~* any subject judged to be medically inappropriate for study participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- 20 mg ITI-007 (Type: EXPERIMENTAL): 20 mg ITI-007 administered orally as formulated capsules once daily for 6 weeks
- 60 mg ITI-007 (Type: EXPERIMENTAL): 60 mg ITI-007 administered orally as formulated capsules once daily for 6 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo administered orally as visually-matched capsules once daily for 6 weeks
- Risperidone (Type: ACTIVE_COMPARATOR): Risperidone administered orally as visually-matched over-encapsulated tablet once daily for 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).